Dexcom Ends 2023 with 2 Blockbuster Collaborations in Diabetes

Dexcom is strengthening its G7 Continuous Glucose Monitor sensor’s position in the diabetes management space with two blockbuster collaborations. The San Diego, CA-based firm revealed agreements with Beta Bionics and Tandem Diabetes.

Late last week, Concord, MA-based Beta Bionics said it would integrate the G7 CGM sensor into its iLet Bionic Pancreas automated insulin delivery system, which is set to launch December 18th. Beta Bionics said with a firmware update, users will be able to update their iLet to integrate with Dexcom G7 without any additional cost for new hardware.

The company won a nod from FDA for the technology in May.

“Our goal is to give our patients choice with their CGM technology and to be able to update quickly and easily without new hardware or additional costs,” Sean Saint, CEO at Beta Bionics, said in a release. “We truly appreciate our partnership with Dexcom and their speed and adaptability. Once we established our timeline, we were able to rapidly integrate, test, and launch with Dexcom G7 in only four months. It’s a clear testament to our teams working in unison with a common goal of providing the latest technology to help users manage their diabetes with less work and less burden.”

Before the Beta Bionics announcement, Tandem reported the launch of updated t:slim X2 insulin pump software with Dexcom G7 CGM integration in the U.S.

Tandem said it will email instructions to all in-warranty t:slim X2 users in the United States to offer the option to add the new feature free of charge via remote software update. t:slim X2 pumps pre-loaded with the updated software are now shipping to new customers.

“With this launch, we are offering more than 300,000 current t:slim X2 users the ability to integrate with Dexcom’s most advanced CGM technology, demonstrating our commitment to continued leadership in advancing AID systems,” said John Sheridan, president and chief executive officer of Tandem Diabetes Care. “As we celebrate our 10-year partnership with Dexcom, we remain committed to sustaining our rapid pace of innovation to further our mission of helping improve the lives of people with diabetes.”

The two partnerships bring a close to an eventful year for Dexcom. The company began the year with the launch of the G7. After a few delays the company finally obtained clearance for the device at the end of 2022.

In April, Dexcom and other companies in the CGM space benefited from the Centers for Medicare & Medicaid Service expanding coverage to a broader group of beneficiaries with diabetes after removing the prior requirement of multiple daily insulin injections to be eligible for reimbursement.